secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2026-05-14T20:15:18+00:00
Accession:  0001193125-26-224065
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026
-----------------------------------------------------------------------------

- Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.
- Q1 revenue $14.5M (down from $17.4M YoY); total R&D+G&A $44.1M (down from $64.9M YoY).
- STRO-004 Phase 1 dose-escalation ongoing; initial safety, PK, activity data expected mid-2026.
- Astellas collaboration: first TROP2 dual-payload iADC in clinic; $10M milestone received April 2026.
- Luvelta program closed; no further investment or business development efforts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/0001193125-26-224065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer